Page last updated: 2024-08-23

preclamol and MPTP Neurotoxicity Syndrome

preclamol has been researched along with MPTP Neurotoxicity Syndrome in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brown-Borg, HM; Ebadi, M; Muralikrishnan, D1
Sonsalla, PK; Terleckyj, I1

Other Studies

2 other study(ies) available for preclamol and MPTP Neurotoxicity Syndrome

ArticleYear
Dopamine agonist 3-PPP fails to protect against MPTP-induced toxicity.
    Neurochemical research, 2004, Volume: 29, Issue:2

    Topics: Animals; Behavior, Animal; Cell Division; Cell Line, Tumor; Corpus Striatum; Dopamine; Dopamine Agonists; Humans; Mice; Mice, Inbred C57BL; Monoamine Oxidase; MPTP Poisoning; Neuroprotective Agents; Piperidines; Treatment Failure

2004
The sigma receptor ligand (+/-)-BMY 14802 prevents methamphetamine-induced dopaminergic neurotoxicity via interactions at dopamine receptors.
    The Journal of pharmacology and experimental therapeutics, 1994, Volume: 269, Issue:1

    Topics: Animals; Anticonvulsants; Antipsychotic Agents; Brain Diseases; Butaclamol; Carbazoles; Dizocilpine Maleate; Dopamine; Dopamine Agents; Drug Interactions; Drug Synergism; Guanidines; Ligands; Male; Methamphetamine; Mice; MPTP Poisoning; Neostriatum; Piperidines; Psychotropic Drugs; Pyrimidines; Receptors, Dopamine; Receptors, sigma; Stereoisomerism; Tyrosine 3-Monooxygenase

1994